The trading price of Pasithea Therapeutics Corp (NASDAQ:KTTA) closed higher on Tuesday, May 06, and closing at $1.52, 7.04% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $7.69 and a 52-week low of $0.92. Over the past month, the stock has gained 19.69% in value.
Pasithea Therapeutics Corp, whose market valuation is $4.50 million at the time of this writing, is expected to release its quarterly earnings report in June. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest KTTA has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
A quick review shows that KTTA’s price is currently 3.23% off the SMA20 and 16.42% off the SMA50. The RSI metric on the 14-day chart is currently showing 52.85, and weekly volatility stands at 41.16%. When measured over the past 30 days, the indicator reaches 22.94%. Pasithea Therapeutics Corp (NASDAQ:KTTA)’s beta value is currently sitting at 0.53, while the Average True Range indicator is currently displaying 0.35.
To see how Pasithea Therapeutics Corp stock has been performing in comparison to its peers in the industry, here are the numbers: KTTA stock’s performance was 7.04% in the latest trading, and -78.56% in the past year.
An evaluation of the daily trading volume of Pasithea Therapeutics Corp (NASDAQ:KTTA) indicates that the 3-month average is 1.85 million.
Currently, records show that 2.96 million of the company’s shares remain outstanding. The insiders hold 19.08% of outstanding shares, whereasinstitutions hold 2.61%. However, since the stock’s price has seen -51.75% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
